Niladri Das*

*Corresponding Author: Niladri Das..

Received: December 20, 2024; Published: February 20, 2025

Abstract

Bone health in transgender individuals is crucial yet frequently neglected, requiring attention from treating physicians. Before starting gender-affirming hormone treatment (GAHT), transwomen typically exhibit lower bone mineral density (BMD) compared to cisgender men, likely due to hormone-independent factors. BMD significantly increases within the first year of GAHT, then gradually declines, though it remains above baseline levels. In transmen, BMD before and after GAHT closely aligns with that of cisgender women. It is essential to adhere to the International Society for Clinical Densitometry guidelines when ordering, performing, or interpreting a BMD scan for gender-diverse patients. While the risk of fragility fractures varies between transmen and transwomen, the fracture sites and characteristics mirror those seen in the cisgender population.

Keywords: Transgender; Bone Health; GAHT; BMD

References

1. Hembree WC., et al. “Endocrine treatment of gender-dysphoric/Gender-incongruent persons: an endocrine society Clinical practice guideline”. The Journal of Clinical Endocrinology and Metabolism 102 (2017): 3869-3903.
2. Herman JL., et al. “How Many Adults and Youth Identify as Transgender in the United States?”. Los Angeles, CA: The Williams Institute, UCLA School of Law (2022).
3. van Leerdam TR., et al. “The effect of genderafrming Hormones on gender dysphoria, quality of life, and Psychological functioning in transgender individuals: a systematic Review”. Transgend Health1 (2023): 6-21.
4. Falahati-Nini A., et al. “Relative Contributions of testosterone and estrogen in Regulating bone resorption and formation in Normal elderly men”. The Journal of Clinical Investigation12 (2000): 1553-1560.
5. Rothman MS and Iwamoto SJ. “Bone health in The transgender population”. Clinical Reviews in Bone and Mineral Metabolism 2 (2018): 77-85.
6. Almeida M., et al. “Estrogens and Androgens in skeletal physiology and pathophysiology”. Physiology Review 1 (2011): 135-187.
7. Klink D., et al. “Bone mass in young adulthood following gonadotropin-releasing Hormone analog treatment and cross-sex hormone treatment in Adolescents with gender dysphoria”. The Journal of Clinical Endocrinology and Metabolism2 (2015): E270-275.
8. Burinkul S., et al. “Anti-androgenic effects comparison between Cyproterone acetate and spironolactone in Transgender women: a randomized controlled Trial”. The Journal of Sexual Medicine 18 (2021): 1299-1307.
9. Kuijpers SME., et al. “Toward a lowest effective dose of Cyproterone acetate in trans women: results from The ENIGI study”. The Journal of Clinical Endocrinology and Metabolism 106 (2021): e3936-e3945.
10. Giacomelli GMM and Meriggiola MC. “Bone Health in transgender people: a narrative Review”. Therapeutic Advances in Endocrinology and Metabolism 13 (2022): 20420188221099346.
11. Pelusi C., et al. “Effects Of three different testosterone formulations in Female-to-male transsexual persons”. The Journal of Sexual Medicine 11 (2014): 3002-3011.
12. Delgado-Ruiz R., et al. “Systematic review of the long-term effects of Transgender hormone therapy on bone Markers and bone mineral density and their Potential effects in implant therapy”. Journal of Clinical Medicine6 (2019): 784.
13. Bretherton I., et al. “Bonemicroarchitecture in transgender adults: across-sectional study”. Journal of Bone and Mineral Research4 (2022): 643-648.
14. Ford K., et al. “Characterising Body composition and bone health in Transgender individuals receiving genderaffirming Hormone therapy”. Journal of Human Nutrition and Dietetics6 (2022): 1105-1114.
15. Van Caenegem E., et al. “Low bone mass is prevalent in male-to-female Transsexual persons before the start of cross-sex Hormonal therapy and gonadectomy”. Bone 54 (2013): 92-97.
16. Van Caenegem E., et al. “Preservation of volumetric bone Density and geometry in trans women during Cross-sex hormonal therapy: a prospective Observational study”. Osteoporosis International1 (2015): 35-47.
17. Dobrolin´ska M., et al. “Bone mineral density in transgender individuals After gonadectomy and long-term genderaffirming Hormonal treatment”. The Journal of Sexual Medicine 16 (2019): 1469-1477.
18. Ruetsche AG., et al. “Cortical and trabecular bone mineral Density in transsexuals after long-term cross-sex Hormonal treatment: a cross-sectional study”. Osteoporosis International 16 (2005): 791-798.
19. Lapauw B., et al. “Body Composition, volumetric and areal bone Parameters in male-to-female transsexual persons”. Bone 43 (2008): 1016-1021.
20. T’Sjoen G., et al. “Prevalence of Low bone mass in relation to estrogen treatment And body composition in male-to-female Transsexual persons”. Journal of Clinical Densitometry 12 (2009): 306-313.
21. Van Caenegem E., et al. “Body Composition, bone turnover, and bone mass in Trans men during testosterone treatment: 1-year Follow-up data from a prospective case-controlled Study (ENIGI)”. European Journal of Endocrinology 172 (2015): 163-171.
22. López-Cañada E., et al. “Physical activity and sport in trans Persons before and after gender disclosure: Prevalence, frequency, and type of activities”. Journal of Physical Activity and Health 17 (2020): 650-656.
23. Orsso CE., et al. “Low Muscle mass and strength in pediatrics patients: Why should we care?” Clinical Nutrition 38 (2019): 2002-2015.
24. Goodrich E., et al. “Bone Health in the Transgender Population”. JBJS Review10 (2023).
25. Wiepjes CM., et al. “Bone Safety during the first ten years of genderaffirming hormonal Treatment in transwomen and transmen”. Journal of Bone and Mineral Research3 (2019): 447-454.
26. Goh HH and Ratnam SS. “Effects of hormone Deficiency, androgen therapy and calcium Supplementation on bone mineral density in Female transsexuals”. Maturitas 26 (1997): 45-52.
27. Rosen HN., et al. “Bone densitometry in transgender and gender non-conforming (TGNC) individuals: 2019 ISCD official position”. Journal of Clinical Densitometry4 (2019): 544-53.
28. Fighera TM., et al. “Impact of cross-sex hormone therapy on bone mineral density And body composition in transwomen”. Clinical Endocrinology (Oxf)6 (2018): 856-862.
29. Broulik PD., et al. “Eighteen-year Effect of androgen therapy on bone mineral density in trans (gender) men”. Hormone and Metabolic Research2 (2018): 133-137.
30. Van Caenegem E., et al. “Bone Mass, bone geometry, and body composition in female-tomale Transsexual persons after long-term cross-sex hormonal Therapy”. The Journal of Clinical Endocrinology and Metabolism7 (2012): 2503-2511.
31. Lips P., et al. “The effect of androgen treatment on bone metabolism In female-to-male transsexuals”. Journal of Bone and Mineral Research11 (2009): 1769-1773.
32. Wentzel D., et al. “A retrospective analysis of fractures in the Transgender population [abstract]”. In: Southern Medical Association’s Physicians-in-Training Leadership Conference; (2023).
33. Wiepjes CM., et al. “Bone mineral density increases in trans Persons after 1 year of hormonal treatment: A multicenter prospective observational Study”. Journal of Bone and Mineral Research6 (2017): 1252-1260.
34. Stevenson MO and Tangpricha V. “Osteoporosis And bone health in transgender persons”. Endocrinology and Metabolism Clinics of North America 2 (2019): 421-427.
35. Verroken C., et al. “Osteoporosis and bone health in transgender Individuals”. Calcified Tissue International5 (2022): 615-623.
36. Wierckx K., et al. “Long-term evaluation of cross-sex hormone treatment in transsexual persons”. The Journal of Sexual Medicine 9 (2012): 2641-2651.
37. Wiepjes CM., et al. “Fracture risk in trans women and trans men using long-term gender-affirming hormonal treatment: a nationwide cohort study”. Journal of Bone and Mineral Research1 (2020): 64-70.
38. Motta G., et al. “Fracture risk assessment in an Italian group of transgender women after gender-confirming surgery”. Journal of Bone and Mineral Metabolism6 (2020): 885-893.

Citation

Citation: Niladri Das. “Bone Health in Transgender Individuals". Acta Scientific Clinical Case Reports 6.3 (2025): 28-32.

Copyright

Copyright: © 2025 Niladri Das. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.